Effects of empagliflozin on functional capacity, LV filling pressure, and cardiac reserves in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction: a randomized controlled open-label trial

Table 4 Dynamics of biomarker levels in the study groups after 6 months of follow-up

Variables	Empagliflozin (n = 35)		Control (n = 35)		Difference between groups (95% CI)	P Value for intergroup differences
Variables	Baseline	Change from baseline (95% CI)	6 months	Change from baseline (95% CI)	Difference between groups (95% CI)	P Value for intergroup differences
NT-proBNP, pg/mL	214 (163–258)	− 11 (− 50, 57)	240 (180–431)	28 (5, 72)	53 (3, 95)	0.038
NT-proBNP > mediane, pg/mL	261 (228–332)	− 61 (− 121, − 2)	432 (286–644)	80 (6, 173)	130 (54, 238)	0.0029
sST2, ng/mL	25.9 (13.3–28.3)	− 1.2 (− 2.9, − 0.4)	24.4 (18.5–27.9)	0.9 (− 0.3, 2.1)	2.3 (0.9, 3.8)	0.019
sST2 > mediane, ng/mL	28.3 (27.7–31.0)	− 1.5 (− 3.2, 0.4)	27.5 (25.3–32.9)	1.6 (− 0.2, 3.2)	3.1 (1.2, 5.0)	0.0014
hsCRP, mg/L	2.1 (0.7–3.3)	− 0.3 (− 0.8, 0.1)	1.6 (0.8–2.9)	− 0.1 (− 0.4, 0.5)	0.4 (− 0.1, 1.0)	0.057
hsCRP > mediane, mg/L	3.3 (2.5–6.3)	− 0.8 (− 2.7, 0.1)	2.9 (2.0–6.0)	− 0.3 (− 1.2, 0.5)	0.3 (− 0.7, 1.4)	0.33

Baseline and follow-up data are presented as medians (interquartile ranges), and the dynamics of the variables are presented as the mean change from the baseline values (95% confidence intervals)
hsCRP High-sensitivity C-reactive protein, NT-proBNP N-terminal pro–brain natriuretic peptide, sST2 Soluble interleukin 1 receptor-like 1

ISSN: 1475-2840